Covid 19 Research using Clinical Trials (Home Page)
OseltamivirWiki
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (10)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug30 | ASC09F+Oseltamivir Wiki | 0.45 |
| drug385 | ECCO2R Wiki | 0.45 |
| drug970 | Ritonavir+Oseltamivir Wiki | 0.45 |
| drug1311 | hormones Wiki | 0.45 |
| drug1341 | mesenchymal stem cells Wiki | 0.45 |
| drug35 | Abidol hydrochloride Wiki | 0.32 |
| drug1365 | oxygen therapy Wiki | 0.32 |
| drug647 | Lopinavir/ritonavir Wiki | 0.13 |
| drug108 | Azithromycin Wiki | 0.08 |
| drug505 | Hydroxychloroquine Wiki | 0.05 |
Correlated MeSH Terms (7)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D007251 | Influenza, Human NIH | 0.17 |
| D012141 | Respiratory Tract Infections NIH | 0.10 |
| D011014 | Pneumonia NIH | 0.10 |
| D055371 | Acute Lung Injury NIH | 0.06 |
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.06 |
| D012128 | Respiratory Distress Syndrome, Adult NIH | 0.05 |
| D007239 | Infection NIH | 0.03 |
Correlated HPO Terms (2)
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0011947 | Respiratory tract infection HPO | 0.10 |
| HP:0002090 | Pneumonia HPO | 0.10 |
There are 5 clinical trials
Clinical Trials
1 SEA022 Oseltamivir Treatment in Children Under One Year of Age With Moderate or Severe Influenza Lower Respiratory Tract Infection - a Clinical and Pharmacokinetic Study.
Currently, there is no treatment for children less than one year of age with influenza related lower respiratory tract infection that is either considered standard or registered in any country. This dismal scenario exists even though influenza related LRTI is a significant illness causing morbidity and mortality, especially in children less than 6 months of age. Avian influenza has been reported rarely in children less than one. There are no data in Vietnam and very few data in Thailand on the burden of influenza in children less than one. This young age group suffers high mortality. Oseltamivir may be beneficial in such children. This is basis of this trial.
NCT01546935 Influenza Drug: Oseltamivir MeSH:Infection Respiratory Tract Infections Influenza, Human
HPO:Respiratory tract infection
Primary Outcomes
Description: Viral clearance on Day 5 (human influenza) on a throat swab, assessed by RT PCR.
Viral clearance on Day 10 (avian influenza) on a throat swab, assessed by RT PCR.
Measure: Viral clearance Time: 5-10 days
Description: • Cmax, Tmax, AUC, apparent volume of distribution, clearance, terminal elimination half-life
Measure: Pharmacokinetics of Oseltamivir Time: Day 0 and Day 9
Secondary Outcomes
Description: Time to viral clearance on a throat swab, assessed by RT PCR.
The time to no detectable influenza virus by culture for the throat swab.
Change in viral load (log10 copies/mL) over time for all virological samples (lower limit of detection: 1000 copies/mL)
Viral susceptibility of cultured influenza virus to antiviral drugs at baseline and post treatment, assessed by genotypical and phenotypical analyses
Measure: Viral end points Time: 5-10 days
Description: Time to fever clearance
In hospital mortality and mortality by follow up
Time to death
Time to trans cutaneous O2 saturation of ≥ 95% on room air
Clinical course: pneumothorax, encephalitis/encephalopathy
Number of days in hospital
Number of days ventilated
Measure: Clinical Efficacy Endpoints Time: 5-10 days
Description: Documented serious adverse events (SAEs) and relationships to oseltamivir
AEs leading to drug withdrawal
Grade 3 & 4 clinical and laboratory AEs that are probably or definitely related to oseltamivir
Skin rashes of any grade
Changes in haematological and biochemical parameters over time
Measure: Safety Endpoints Time: 5-10 days
2 An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Three Antiviral Drugs(Abidol Hydrochloride, Oseltamivir and Lopinavir/Ritonavir) in the Treatment of 2019-nCoV Pneumonia.
Primary Outcomes
Description: Viral clearance on Day 5 (human influenza) on a throat swab, assessed by RT PCR. Viral clearance on Day 10 (avian influenza) on a throat swab, assessed by RT PCR.
Measure: Viral clearance Time: 5-10 daysDescription: • Cmax, Tmax, AUC, apparent volume of distribution, clearance, terminal elimination half-life
Measure: Pharmacokinetics of Oseltamivir Time: Day 0 and Day 9Secondary Outcomes
Description: Time to viral clearance on a throat swab, assessed by RT PCR. The time to no detectable influenza virus by culture for the throat swab. Change in viral load (log10 copies/mL) over time for all virological samples (lower limit of detection: 1000 copies/mL) Viral susceptibility of cultured influenza virus to antiviral drugs at baseline and post treatment, assessed by genotypical and phenotypical analyses
Measure: Viral end points Time: 5-10 daysDescription: Time to fever clearance In hospital mortality and mortality by follow up Time to death Time to trans cutaneous O2 saturation of ≥ 95% on room air Clinical course: pneumothorax, encephalitis/encephalopathy Number of days in hospital Number of days ventilated
Measure: Clinical Efficacy Endpoints Time: 5-10 daysDescription: Documented serious adverse events (SAEs) and relationships to oseltamivir AEs leading to drug withdrawal Grade 3 & 4 clinical and laboratory AEs that are probably or definitely related to oseltamivir Skin rashes of any grade Changes in haematological and biochemical parameters over time
Measure: Safety Endpoints Time: 5-10 daysAt present, there is no specific and effective antiviral therapy.In this study, an open, prospective/retrospective, randomized controlled cohort study was designed to compare the efficacy of three antiviral drugs in the treatment of 2019-nCoV pneumonia by studying the efficacy of abidol hydrochloride, oseltamivir and lopinavir/ritonavir in the treatment of 2019-nCoV viral pneumonia, and to explore effective antiviral drugs for new coronavirus. To provide reliable evidence-based medicine basis for the treatment of viral pneumonia caused by new coronavirus infection.
NCT04255017 2019-nCoV Drug: Abidol hydrochloride Drug: Oseltamivir Drug: Lopinavir/ritonavir MeSH:Pneumonia
HPO:Pneumonia
Primary Outcomes
Description: A: For mild patients : fever, cough and other symptoms relieved with improved lung CT; B:For severe patients : fever, cough and other symptoms relieved with improved lung CT,SPO2> 93% or PaO2/FiO2>300mmHg (1mmHg=0.133Kpa);
Measure: Rate of disease remission Time: two weeks
Description: Compare the average time of lung imaging recovery after 2 weeks of treatment in each group.
Measure: Time for lung recovery Time: two weeks
Secondary Outcomes
Measure: Rate of no fever Time: two weeks
Measure: Rate of respiratory symptom remission Time: two weeks
Measure: Rate of lung imaging recovery Time: two weeks
Measure: Rate of CRP,ES,Biochemical criterion(CK,ALT,Mb) recovery Time: two weeks
Measure: Rate of undetectable viral RNA Time: two weeks
3 A Randomized,Open,Controlled Small Sample Clinical Study to Evaluate the Efficacy and Safety of ASC09/Ritonavir Compound Tablets and Ritonavir for 2019-nCoV Pneumonia
Primary Outcomes
Description: A: For mild patients : fever, cough and other symptoms relieved with improved lung CT; B:For severe patients : fever, cough and other symptoms relieved with improved lung CT,SPO2> 93% or PaO2/FiO2>300mmHg (1mmHg=0.133Kpa);
Measure: Rate of disease remission Time: two weeksDescription: Compare the average time of lung imaging recovery after 2 weeks of treatment in each group.
Measure: Time for lung recovery Time: two weeksSecondary Outcomes
Measure: Rate of no fever Time: two weeksMeasure: Rate of respiratory symptom remission Time: two weeks
Measure: Rate of lung imaging recovery Time: two weeks
Measure: Rate of CRP,ES,Biochemical criterion(CK,ALT,Mb) recovery Time: two weeks
Measure: Rate of undetectable viral RNA Time: two weeks
Based on oseltamivir treatment, evaluate the efficacy and safety of ASC09/ritonavir compound tablets(ASC09F) or ritonavir tablets for 2019-nCoV infection patients.
NCT04261270 2019-nCoV Pneumonia Drug: ASC09F+Oseltamivir Drug: Ritonavir+Oseltamivir Drug: Oseltamivir MeSH:Pneumonia
HPO:Pneumonia
Primary Outcomes
Description: The definition of comprehensive adverse outcome is as follows:
SPO2≤93% without oxygen inhalation;
PaO2/FiO2≤300mmHg;
RR≥30 bpm without oxygen inhalation.
Measure: Rate of comprehensive adverse outcome Time: 14 days
Secondary Outcomes
Description: The definition of clinical remission:
Based on the symptoms of the disease (fever,cough,diarrhea,myalgia,dyspnea) has been relieved for 48 hours;
There is no evidence of disease progression(New dyspnea, SpO2 decreased≥3%,RR≥30 bpm without oxygen inhalation).
Measure: Time of clinical remission Time: 28 days
Measure: Rate of no fever Time: 14 days
Measure: Rate of no cough Time: 14 days
Measure: Rate of no dyspnea Time: 14 days
Measure: Rate of no need for oxygen inhalation Time: 14 days
Measure: Rate of undetectable viral RNA Time: 14 days
Measure: Rate of mechanical ventilation Time: 28 days
Measure: Rate of ICU admission Time: 28 days
Measure: Rate and time of CRP,ES,Biochemical criterion(CK,ALT,Mb)recovery Time: 28 days
4 Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment
Primary Outcomes
Description: The definition of comprehensive adverse outcome is as follows: SPO2≤93% without oxygen inhalation; PaO2/FiO2≤300mmHg; RR≥30 bpm without oxygen inhalation.
Measure: Rate of comprehensive adverse outcome Time: 14 daysSecondary Outcomes
Description: The definition of clinical remission: Based on the symptoms of the disease (fever,cough,diarrhea,myalgia,dyspnea) has been relieved for 48 hours; There is no evidence of disease progression(New dyspnea, SpO2 decreased≥3%,RR≥30 bpm without oxygen inhalation).
Measure: Time of clinical remission Time: 28 daysMeasure: Rate of no fever Time: 14 days
Measure: Rate of no cough Time: 14 days
Measure: Rate of no dyspnea Time: 14 days
Measure: Rate of no need for oxygen inhalation Time: 14 days
Measure: Rate of undetectable viral RNA Time: 14 days
Measure: Rate of mechanical ventilation Time: 28 days
Measure: Rate of ICU admission Time: 28 days
Measure: Rate and time of CRP,ES,Biochemical criterion(CK,ALT,Mb)recovery Time: 28 days
To evaluate the effectiveness of Hydroxychloroquine Phosphate/Sulfate (200 mg orally 8hr thrice a day for 5 days) vs oseltamivir (75 mg orally twice a day for 5 days) vs Azithromycin (500 mg orally daily on day 1, followed by 250 mg orally twice a day on days 2-5) alone and in combination (in all seven groups), in clearing the coronavirus nucleic acid from throat and nasal swab and in bringing about clinical improvement on day 7 of follow-up (primary outcomes).
NCT04338698 COVID 19 Drug: Hydroxychloroquine Drug: Oseltamivir Drug: Azithromycin
Primary Outcomes
Description: The laboratory-based primary outcome will be turning test negative for COVID-19 on RT-qPCR calculated as viral load of < 150 i.u
Measure: Laboratory Result Time: Day 07 on follow-upDescription: The clinical primary outcome will be improvement of two points on a seven-category ordinal scale shown below: Not hospitalized, able to resume normal activities Not hospitalized, but unable to resume normal activities Hospitalization, not requiring supplemental oxygen Hospitalization, requiring supplemental oxygen Hospitalization, requiring noninvasive mechanical ventilation Hospitalization, requiring invasive mechanical ventilation Death
Measure: Clinical Outcome Time: Day 07 on follow-up5 Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019
The outbreak of coronavirus disease 2019 (COVID-19) at the end of 2019 has seen numerous patients experiencing severe acute lung injury (ALI), which developed into severe respiratory distress syndrome (ARDS). The mortality was as high as 20% -40%. Due to the lack of effective antiviral treatments, supporting treatment is the predominant therapy for COVID-19 pneumonia. Its cure is essentially dependent on the patient's immunity. While the immune system eliminates the virus, numerous inflammatory cytokines are produced and a cytokine storm occurs in severe cases. Mesenchymal stem cells (MSCs) play an important role in injury repair and immune regulation, showing advantageous prospects in the treatment of COVID-19 pneumonia. MSCs prevent cytokine storms by retarding the TNF-α pathway, alleviate sepsis by modulating macrophages, neutrophils, NK cells, DC cells, T lymphocytes and B lymphocytes. After infused, MSCs aggregate in the lungs, improve the lung microenvironment, protect alveolar epithelia, and improve pulmonary fibrosis and pulmonary function.
NCT04371601 COVID-19 Pneumonia Drug: Oseltamivir Drug: hormones Device: oxygen therapy Procedure: mesenchymal stem cells MeSH:Pneumonia
HPO:Pneumonia
Primary Outcomes
Description: Improvement of pulmonary function
Measure: Changes of oxygenation index (PaO2/FiO2) ,blood gas test Time: 12 months
Secondary Outcomes
Description: Cytokines level
Measure: Detection of TNF-α levels, IL-10 levels Time: 1,3,6,12months
Description: Immunological status
Measure: Detection of immune cells that secret cytokines, including CXCR3+, CD4+, CD8+, NK+ cells, and regulatory T cells (CD4 + CD25 + FOXP3 + Treg cells). Time: 1,3,6,12months
Description: Improvement of pulmonary function
Measure: Changes of oxygenation index (PaO2/FiO2) ,blood gas test Time: 1,3,6months
Description: Infection biomarkers
Measure: Changes of c-reactive protein and calcitonin Time: 1,3,6,12months
Related HPO nodes (Using clinical trials)
HP:0002090: Pneumonia
Genes 211
CCDC103 JAK3 IL2RG CD247 DNAI1 DOCK8 CSPP1 RYR1 IL2RG DNAAF2 JAK3 OFD1 PRKCD RSPH4A IGHM CCNO GAS8 DCLRE1C ZBTB24 NOTCH3 ZAP70 OSTM1 TK2 LRRC56 TGFB1 NKX2-1 DNAH11 CHD7 FOXP3 RANBP2 DNAI2 CR2 RNU4ATAC SETBP1 NADK2 SPAG1 COL11A2 TNFRSF13C SFTPC HYDIN DNAH9 IL2RG SRP54 TNFSF12 ICOS FCGR2A ADA DNAH5 GRHL3 UBB AFF4 KIAA0586 IL7R TERT DNAH1 DNAI1 ORC6 MASP2 DCLRE1C RSPH3 MTHFD1 AFF4 IRF8 ELANE CCDC39 NME8 CASP8 CARD11 DNAAF4 SLC35C1 EPM2A CD81 KMT2D TNFSF12 UNC119 LRBA NCF2 USB1 CCDC114 NBN DCLRE1C RMRP NFKB2 SFTPA2 RSPH1 RAG2 ADA EGFR CCDC114 WAS TNFRSF13C KDM6A IL21R TNFRSF13B TBC1D24 ICOS SLC25A24 NFKB1 PNP NFIX RAG1 ARMC4 ADA STAT3 DNMT3B RAG2 CFAP300 BTK GFI1 TAF1 SPEF2 RNF125 IL2RG NCF1 TNFRSF13C CXCR4 CARD11 CD55 OFD1 CCDC151 FOXJ1 ZMYND10 PEPD GNPTAB RAG1 PIGN ALMS1 MED25 CFAP410 BTK RAC1 ACP5 ACTA1 CD19 GBA TNFRSF11A CD79B DRC1 SMARCD2 NFKB2 STK36 ZAP70 RNU4ATAC DNAAF3 P4HTM RSPH9 SAMD9 IGLL1 RPGR TNFRSF13B LTBP3 DNAL1 CFAP298 CYBA BTK MS4A1 ICOS DNAAF1 LIG4 CR2 ACADVL RAG1 GAS2L2 NSMCE3 CFAP221 SGCG FMO3 DNAAF6 DNAAF5 TTC25 PMM2 COL11A2 TCIRG1 TIMM8A SELENON RAG2 MUC5B SLC35A1 PGM3 EXTL3 KPTN CACNA1C CD3E CD19 CYBB LRRC6 KCNJ6 RNF168 IFNGR1 CD3D GAS8 CFTR PLOD1 POLA1 NBN PANK2 BLNK CFB WDR19 IL7R SP110 MCIDAS PTPRC TBCD CCDC40 NIPBL LEP NHLRC1 DDR2 DNAJB13 CCDC65 SNP 0
HP:0011947: Respiratory tract infection
Genes 645
CCDC103 GATA6 IL2RG COL13A1 NCF4 DNAI1 EPG5 CSPP1 RYR1 ABCA12 CACNA1B IL2RG POLR3A DNAAF2 TRAIP CLCA4 JAK3 SOX11 OFD1 IL17RC SLC12A6 IGHM TCTN3 NECTIN1 INSR IER3IP1 GAS8 DCLRE1C BCR NOTCH3 CLEC7A PSAP VPS33A LRRC56 PWRN1 ATM TGFB1 BCL10 RAG2 CCDC39 CD8A NKX2-1 OCRL DNAH11 CHD7 TINF2 FOXP3 RANBP2 CR2 RNU4ATAC SETBP1 CD3D MALT1 PLP1 HYDIN SPAG1 TAP2 AGA IRAK4 DNAH9 NELFA IL7R TNFSF12 RUNX2 DNAAF4 IL17RA ADA DNAI2 DNAH5 GRHL3 FOXP1 ATP6V0A2 DNAH1 LCK DNAI1 SMARCA4 ORC6 ELP1 MASP2 DCLRE1C SLC5A7 RSPH3 MTHFD1 NIPAL4 G6PC3 CCNO IRF8 CHAMP1 SLC52A3 CCDC39 PIK3CD SDCCAG8 NHP2 EPM2A SCNN1A MYSM1 CD81 TNFSF12 UNC119 CCDC65 ARMC4 RAG1 ARID2 LRBA NCF2 SMN1 CDCA7 FLNA DCLRE1C RMRP TBC1D23 TPM3 NFKB2 DSG1 NKX2-1 SFTPA2 SMPD1 UBE2A RAG2 FAT4 SNORD116-1 IPW MYO5A WAS CFTR KDM6A ICOS RYR1 SLC25A22 NFKB1 DNAH11 RPGR RAG1 SOX4 NCF1 ARSB NME8 ALMS1 ARMC4 DCLRE1C TSC1 STAT3 STAT3 CR2 TSC1 RAB3GAP2 GFI1 ARID1A TAF1 HACD1 ALB RNF125 ADAMTS3 UMPS LAMTOR2 LEPR SMARCB1 IDUA CARD11 LAMB2 CFTR CCDC151 USP9X LEP TECPR2 DNMT3B RSPH4A COL6A1 TNFSF11 BIRC3 RYR1 PRKDC GLB1 TYK2 PEPD HLA-DPA1 TCIRG1 LRRC56 CFTR FBLN5 SNORD115-1 TNFRSF13B SCNN1G GNPTAB CORO1A CXCR4 DNAAF6 IDUA SNX10 MED25 CFAP410 FCGR3A BTK GMNN ABCA12 RAC1 ACP5 EDARADD CD19 POLE GBA LAMA2 STAT1 LIPN NFKB2 DRC1 VPS13A WAS NFKB1 NFKB2 STK36 AK2 MGP GBA CCDC22 SLC1A4 RNF113A DNAJB13 SULT2B1 BLM TAP1 INPPL1 TNFRSF1A CFAP298 ZBTB24 PIK3R1 RPGR DNAH5 DNAL1 CFAP298 GATA2 BTK SMPD1 ICOS DCTN4 DKC1 FUCA1 DNAAF1 LIG4 CSF2RB ACADVL PRPS1 RAG1 GAS2L2 AGRN RIPK1 FMO3 SNAP25 CSF2RA PTPN22 INPPL1 ALPL MGP MAGEL2 HGSNAT DNAAF5 ELN TTC25 SLC25A1 DNAAF3 RAG2 TGFB1 FCN3 PMM2 RSPH9 CYBB SMARCE1 ASAH1 COL6A3 AICDA SLC35A1 ELANE IKBKB PGM3 CCDC40 CCDC103 ERCC2 KAT6B PEPD KRAS MCM4 CD3E COG4 SPINK5 CD19 SMARCC2 WASHC5 SLC18A3 WRAP53 KCNJ6 GLI3 STING1 MANBA DNAAF5 RFC2 MAPK1 ERCC3 CD3D WIPF1 MS4A1 TERC TGFB1 B2M POLA1 SHROOM4 NBN BLNK CYBC1 CFB IL7R SP110 MCIDAS MYL2 CTLA4 PRTN3 IL2RB CCDC40 EP300 IFIH1 ATM CHAT SCN10A KIF1A GNPTAB CRELD1 DNAJB13 TERT SCNN1B JAK3 ZMYND10 MKRN3-AS1 TPM2 CD247 DOCK8 MBTPS2 SCNN1A TRAF3IP2 PRKCD ACTA1 RSPH4A NGLY1 FLI1 COLQ LETM1 NFE2L2 CCNO RSPH1 TBCE VAMP1 TPP2 SAMD9L ZBTB24 ZAP70 CD3G NR2F2 OSTM1 LAMTOR2 TK2 GUSB CARMIL2 NRAS LRRC8A ARID1B CTCF SELENON LIMK1 GAA SLC46A1 CHRM3 TBL2 MYSM1 DNAI2 SLC29A3 RELB SDR9C7 CD3E NADK2 SPAG1 COL11A2 TNFRSF13C SFTPC RSPH3 SCNN1G IL2RG SH3KBP1 CD79B SRP54 EPG5 ICOS FCGR2A BACH2 UBB AFF4 MAP3K20 KIAA0586 IL7R HPS6 HERC2 TERT GSN RFX5 ERF IKBKB IL17RA SCNN1G LEPR CLCN7 SCN11A DPM2 NCF2 AFF4 EXOSC9 TRPS1 CCBE1 MYH3 ELANE NME8 COG6 CASP8 CARD11 DNAAF4 SLC35C1 DNAAF1 DPF2 KMT2D CD79A CLIP2 USB1 PYROXD1 LYST CCDC114 NBN BLNK TIRAP RFXAP PCGF2 TCF3 MECP2 CTSC TAPBP DNAAF2 NOTCH2 RSPH1 HLA-DPB1 GNS CD81 PGM3 SCNN1B ADA EGFR NCF4 GTF2E2 STAT1 PARN CCDC114 CFI RFXANK TNFRSF13C IL21R MSN TNFRSF13B RFXANK TBC1D24 SLC25A24 SGSH PTPN22 GATA4 PNP NFIX USB1 TSC2 CIITA IDUA GALNS RFXAP ADA DNMT3B RAG2 ITGA3 CFAP300 STX1A EHMT1 ITGA7 ADNP NGLY1 BTK MYO9A TTC25 SPEF2 IL2RG NCF1 ROR2 SCN9A SCNN1A TNFRSF13C MKRN3 NSD2 GTF2H5 ZNHIT3 TARS1 CXCR4 PIK3R1 RTEL1 TRIP11 CD55 OFD1 FOXJ1 HELLS ZMYND10 CYP4F22 NDN ALOXE3 COG4 NFKBIA AP3D1 CD79A PLEC SFTPC GAS2L2 MPLKIP RAG1 ALOX12B IGH RAG1 USP9X PIGN ALMS1 XIAP GBA NXN TFRC TSC2 ACTA1 PNP TNFRSF11A PCNT CD79B HLA-B GTF2I SH2D1A IL21 SMARCD2 ZAP70 RNU4ATAC DNAAF3 IL2RA P4HTM AGA ARID1B RSPH9 SAMD9 IGLL1 GUSB TNFRSF13B LTBP3 CYBA ASAH1 NPM1 IKZF1 CYBA KIAA0556 RFX5 MS4A1 ALG12 JAGN1 SLC26A2 CR2 NAGLU NSMCE3 PLG UNG CFAP221 SGCG COL13A1 DNAAF6 SIK1 LYST SNRPN TRIP4 PWAR1 ECM1 MESP2 TGM1 COL11A2 IRAK4 TCIRG1 TBC1D24 TIMM8A SELENON CD19 RAG2 IKBKG DLL3 MUC5B IL17F NPAP1 ELP1 BAZ1B HYDIN CTLA4 ZNF341 CIITA EXTL3 KPTN CACNA1C XIAP PEX13 PLCG2 COL6A2 CYBB PIK3R1 CTC1 LRRC6 NOP10 RNF168 IFNGR1 GAS8 CFTR PLOD1 SYT2 IGHM PANK2 WDR19 PTPRC MESP2 FOXP1 FLNA TBCD IGLL1 CRKL VPS33A SMN1 NIPBL LEP WDR34 SCNN1B NHLRC1 CCDC151 DOCK8 LRRC6 GTF2IRD1 CREBBP TBX6 DDR2 CCDC65 Protein Mutations 1
H275Y SNP 0
Primary Outcomes
Description: Improvement of pulmonary function
Measure: Changes of oxygenation index (PaO2/FiO2) ,blood gas test Time: 12 monthsSecondary Outcomes
Description: Cytokines level
Measure: Detection of TNF-α levels, IL-10 levels Time: 1,3,6,12monthsDescription: Immunological status
Measure: Detection of immune cells that secret cytokines, including CXCR3+, CD4+, CD8+, NK+ cells, and regulatory T cells (CD4 + CD25 + FOXP3 + Treg cells). Time: 1,3,6,12monthsDescription: Improvement of pulmonary function
Measure: Changes of oxygenation index (PaO2/FiO2) ,blood gas test Time: 1,3,6monthsDescription: Infection biomarkers
Measure: Changes of c-reactive protein and calcitonin Time: 1,3,6,12months